Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer
Familial Alzheimer Disease
Explore 5 assets in Familial Alzheimer Disease →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05269394CT.gov Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) | — | Active Not Recruiting | — | — | — |
NCT01760005CT.gov Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Familial Alzheimer Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer (this asset) | Washington University School of Medicine | P2/3 | B · 57 |
| Lecanemab | Washington University School of Medicine | P3 | BB |
| Remternetug | Washington University School of Medicine | P2/3 | B |
| Solanezumab | Washington University School of Medicine | P2/3 | CCC |
| 2-Bromo-?-ergocryptine | Kyoto University | P1/2 | CCC |
| Immunoglobulin G1, Anti-(Human 1-40-.Beta.-Amyloid/Human 1-42-.Beta.-Amyloid) (Human Monoclonal .Gamma.1-Chain), Disulfide With Human Monoclonal .Kappa.-Chain, Dimer | Washington University School of Medicine | P2/3 | CC |
Other indications for Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P2/3 | BB · 66 |
| Dementia | — | P2/3 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- LecanemabWashington University School of MedicineBB
- RemternetugWashington University School of MedicineB
- SolanezumabWashington University School of MedicineCCC
- 2-Bromo-?-ergocryptineKyoto UniversityCCC
- Immunoglobulin G1, Anti-(Human 1-40-.Beta.-Amyloid/Human 1-42-.Beta.-Amyloid) (Human Monoclonal .Gamma.1-Chain), Disulfide With Human Monoclonal .Kappa.-Chain, DimerWashington University School of MedicineCC
Citation
Floatz Terminal. Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer in Familial Alzheimer Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-de-449-lysine-anti-human-tau-protein-human-mus-musculus-monoclonal-e2814-1-chain-disulfide-with-human-mus-musculus-monoclonal-e2814-kappa-chain-dimer-familial-alzheimer-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →